Summary of the technology
Heterocyclic compounds having a relatively flexible backbone are used to create combinatorial libraries that permit screening for lead compounds and selection of drug candidates for a variety of uses in human and veterinary medicine as well as in agriculture. The compounds of the library generally differ in ring size and chirality of substituents on the ring. Also disclosed are methods for providing and screening these libraries, preferably in an automated or computerizable manner, such as by using a computer program to virtually screen the compounds in order to identify those that are predicted to have bioactive conformations that should give rise to desirable biological effects.
Project ID : 6-2006-53
Description of the technology
Combinatorial libraries of heterocyclic compounds
Drug Discovery, Small Molecules, Conversion of Peptides and Proteins into drug leads
Ongoing projects in various stages
Patents published in U.S. and Europe, filed in IsraelPCT publication number – WO 03/059876
The global protein therapeutic market was valued in excess of US$ 57 billion in 2006, growing at a CAGR of 12.83% till 2010
Preparing libraries of backbone cyclized peptidomietics and macromoecules with conformational diversity, based on active residues from proteins and/or active peptides for screening and selecting drug lead candidates, having improved activity, selectivity, metabolic stability and enhanced intestinal permeability. This technology is applicable to a variety of indications in human medicine, veterinary medicine and in agriculture
Applying this novel technology to a patented target molecule facilitates the speedy development of drug leads
A new technology that converts active regions in proteins and peptides into orally available drug leads.
Faster, more reliable, identification of drug leads
Enables faster pharmacological studies
Cooperation with companies with defined clinical goals and patented molecules to develop drug leads
Licensing agreements with cooperation partners to convert their peptides and proteins into drug leads using new technology
Libraries of drug candidates sold to partners
VP, Business Development, Healthcare
HUJI, Faculty of Science
The Institute of Chemistry
About Yissum - Research Development Company of the Hebrew University
Technology Transfer Office from IsraelYissum - Research Development Company of the Hebrew University
Yissum Research Development Company of the Hebrew University of Jerusalem Ltd. Founded in 1964 to protect and commercialize the Hebrew University’s intellectual property. Ranked among the top technology transfer companies, Yissum has registered over 8,900 patents covering 2,500 inventions; has licensed out 800 technologies and has spun-off 90 companies. Products that are based on Hebrew University technologies and were commercialized by Yissum generate today over $2 Billion in annual sales.